Microfluidic systems redefined biology by providing platforms that handle small fluid volumes, catalyzing advancements in cellular and molecular studies.
At $2 million for a single dose, Novartis’s Zolgensma is the most expensive medicine to date, but still less expensive over a lifetime than another approved drug for the rare genetic disease.
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
A method for culturing the infectious stage of the Plasmodium lifecycle could increase malaria vaccine production efficiency by tenfold, study authors say.